Association of Acute Symptoms of COVID-19 and Symptoms of Depression in Adults | Depressive Disorders | JAMA Network Open | JAMA Network
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777421?resultClick=3&utm_source=STAT+Newsletters&utm_campaign=dd0df333b3-MR_COPY_14&utm_medium=email&utm_term=0_8cab1d7961-dd0df333b3-149703525 After acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a subset of individuals experience persistent symptoms involving mood, sleep, anxiety, and fatigue,1 which may contribute to markedly…
Health workers’ greatest COVID-19 risk is from community, new data show | CIDRAP
https://www.cidrap.umn.edu/news-perspective/2021/03/health-workers-greatest-covid-19-risk-community-new-data-show The greatest COVID-19 risk factors for healthcare personnel (HCP) aren't patient contact or clinical duties but rather community exposure and prevalence, according to a JAMA Network Open study yesterday.…
mRNA COVID vaccination tied to 80% lower risk of asymptomatic infection
https://www.cidrap.umn.edu/news-perspective/2021/03/covid-19-scan-mar-11-2021 mRNA COVID vaccination tied to 80% lower risk of asymptomatic infection A real-world Mayo Clinic study shows a link between vaccination with two doses of an mRNA-based COVID-19 vaccine—either…
CMS visitation Guidance update
QSO-20-39-NH Revised (cms.gov) According to the updated guidance, facilities should allow responsible indoor visitation at all times and for all residents, regardless of vaccination status of the resident, or visitor,…
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial | Infectious Diseases | JAMA | JAMA Network
Question What is the effect of ivermectin on duration of symptoms in adults with mild COVID-19? Findings In this randomized clinical trial that included 476 patients, the duration of symptoms…
JAMA: Acute Allergic Reactions to mRNA COVID-19 Vaccines
Research Letter March 8, 2021 Kimberly G. Blumenthal, MD, MSc1; Lacey B. Robinson, MD, MPH1; Carlos A. Camargo Jr, MD, DrPH2; et alErica S. Shenoy, MD, PhD3; Aleena Banerji, MD1;…
Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir – Merck.com
https://www.merck.com/news/ridgeback-biotherapeutics-and-merck-announce-preliminary-findings-from-a-phase-2a-trial-of-investigational-covid-19-therapeutic-molnupiravir/
Medical Director Report 3-2021
Dr. Shepherd Medical Director Report 3-2021 Click Here for the Report CDPHE COVID-19 Update Presentation 2-24-2021
Colorado COVID-19 Variant Update March 5, 2021
See full health advisory update ● CDPHE has been conducting ongoing surveillance for COVID-19 variants since December 2020, when the first case of B.1.1.7 in Colorado was announced.● As of…